SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are bracing for volatility surrounding a scheduled prime-time address from President Trump regarding the ongoing conflict in Iran, with the community sharply divided between expectations of a 'buy the rumor, sell the news' event and fears of a deeper escalation involving ground troops. Traders are closely monitoring the potential for significant moves in oil and equity indices as the market attempts to decipher whether the administration is signaling a strategic withdrawal or a major military shift.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community fixate on the former President's aggressive rhetoric regarding military escalation in Iran, fueling intense debate over his geopolitical strategy and its impact on the markets. While supporters view his strong posture as a necessary display of dominance, critics are actively highlighting contradictions in his messaging and expressing deep concerns over the potential for prolonged conflict and economic instability.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Market participants are intensely focused on the upcoming presidential address regarding the Iran conflict, with community debate split between expecting a major de-escalation announcement and concerns that the speech will merely justify a continued military presence. Traders are closely monitoring the potential for a 'sell the news' reaction following a sharp rally, while active discussions highlight ongoing uncertainty regarding oil supply and the geopolitical stability of the Strait of Hormuz.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors react to conflicting signals surrounding the Iran-U.S. conflict, with the community actively debating whether recent diplomatic overtures are genuine moves toward de-escalation or tactical market manipulation ahead of an upcoming national address. Despite volatility, traders remain focused on the strategic importance of the Strait of Hormuz and the potential for a sustained geopolitical energy risk premium.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors weigh anticipation for upcoming Q1 delivery results against broader market volatility and speculation surrounding a potential SpaceX IPO. Community discourse remains deeply divided between bullish sentiment regarding the company's long-term autonomy and robotics roadmap, and intense bearish concerns over slowing EV demand and high-profile geopolitical tensions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging as investors react to a strategic $2 billion partnership with Marvell, which is boosting confidence in the AI infrastructure ecosystem. While the stock is catching a massive wave of bullish sentiment, the community remains divided, with many traders closely watching geopolitical developments in the Middle East and upcoming economic reports for signs of further volatility.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to reports that Amazon is in talks to acquire the company, fueling widespread speculation about a potential bidding war involving other major tech players and SpaceX. Community members are actively debating the company's valuation, the strategic value of its spectrum assets in the direct-to-device space, and whether long-term shareholders should hold out for a significant acquisition premium.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense investor scrutiny and volatility as community members weigh the impact of heavy AI infrastructure spending against broader geopolitical tensions and recent software-focused concerns. The stock remains a focal point for institutional put activity, with ongoing debates among traders regarding whether current price levels represent a deep-value opportunity or a precursor to further downside.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense debate over the company's reliance on debt-funded Bitcoin acquisitions, with traders sharply divided between bullish hopes for a massive price recovery and bearish concerns regarding dilution and potential liquidity risks. The stock is seeing high volatility and heavy options activity as market participants closely monitor the underlying performance of Bitcoin and broader macro uncertainties.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently at the center of investor discussion following the company's major $14.2 billion agreement to repurchase a 49% stake in its Ireland Fab 34 facility. The market is actively debating whether this strategic move signals strong future demand and foundry growth or merely adds burdensome debt, while sentiment remains highly volatile due to broader geopolitical tensions in the Middle East and concerns over potential rate fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

43,152 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Royal Fund Management LLC

Royal Fund Management LLC acquired a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities...

<ul class="summary-bullets"><li>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss.</li><li>Structure Therapeutics expects to initiate late-stage clinical development of its experimental drug Aleniglipron in the second half of 2026.</li><li>According to data from Koyfin, GPCR stock carries a 12-month average target of $109, while VKTX stock carries a 12-month average target of $92.72.</li></ul>Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are capturing intense investor attention as obesity treatments are increasingly deemed the largest growth engine in the U.S. pharmaceutical industry.Eli Lilly (LLY) and Novo Nordisk (NVO) currently dominate the current obesity drug market. Smaller firms Viking and Structure are both developing drugs for obesity even as bigger names like Pfizer (PFE) and AstraZeneca (AZN) also seek to enter the competition ring.<h2 class="st-heading-2">Viking, Structure’s Obesity Pipelines</h2>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said.The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.Meanwhile, Structure said earlier this month that its experimental drug Aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks in a mid-stage trial. The company now expects to initiate late-stage clinical development of the drug in the second half of 2026.The company also has other investigational obesity drugs called ACCG-2671 and ANPA-0073 currently in early stage studies. &nbsp;<h2 class="st-heading-2">Who Offers Better Upside?</h2>According to data from Koyfin, GPCR carries a 12-month average target of $109, implying a 147.95% upside potential from its last close. The stock holds a consensus analyst rating of 'Strong Buy', with 15 analysts rating the stock ‘Buy’ or higher while one rates it a ‘Hold’.Meanwhile, VKTX carries a 12-month average target of $92.72, representing a 209.80% upside from current levels. The stock also holds a consensus 'Strong Buy' rating, with 17 analysts rating it ‘Buy’ or higher while two hate it ‘Hold’.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment toward VKTX stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Meanwhile, sentiment toward GPCR stock stayed within the ‘bearish’ territory, while message volume fell from ‘normal’ to ‘low’ levels. &nbsp;<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has climbed 24% this year, while <a href="https://stocktwits.com/symbol/GPCR">GPCR</a> surged 154%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-doubles-down-on-heavy-duty-gas-trucks-amid-massive-ev-writedowns-report/cZERzvHRINm">GM Doubles Down On Heavy-Duty Gas Trucks Amid Massive EV Writedowns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

VKTX Vs. GPCR: Which Obesity Drug Developer Does Wall Street See With The Bigger Upside?

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 

Equity

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 


Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.94, indicating a -7.95% shift from the previous trading day.

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research

Wolfe Research assumed coverage on shares of Viking Therapeutics in a report on Thursday. They set a "peer perform" rating for the company...

<ul class="summary-bullets"><li>Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.</li><li>The company stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735.</li><li>The company stated it expects to complete the VANQUISH studies in 2027.</li></ul>Viking Therapeutics Inc. (VKTX) on Thursday announced that it has completed enrollment in the Phase 3 trial of its obesity drug, VK2735, which is in the race to compete in the GLP-1 obesity drug market, dominated by Novo Nordisk's Ozempic and Wegovy.The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics shares</a> were up nearly 2% in Thursday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.<h2 class="st-heading-2">What Are The Primary And Secondary Endpoints?</h2>Viking Therapeutics stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735, compared to patients on placebo after 78 weeks of treatment.The secondary and exploratory endpoints include an evaluation of several efficacy and safety measures. This includes the percentage of patients who achieve 5%, 10%, 15% and 20% or more body weight reduction during the trial.“As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available,” said Viking CEO Brian Lian.The company stated it expects to complete the VANQUISH studies in 2027.<h2 class="st-heading-2">Phase 3 Trial Update</h2>Viking also announced an update regarding its Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight.The company also stated that it is evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. Results from the maintenance study are expected in the third quarter (Q3) of 2026.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 6% year-to-date, but up 19% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 42% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress

The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Stocktwits

Stocktwits Polls

Investors are speculating on a major acquisition after high-profile mentions on CNBC fueled optimism for a potential deal.

Discussions heat up comparing the efficacy of upcoming treatments against recent competitors like Lilly's newly approved GLP-1.

Community members are actively identifying and flagging a sudden surge in negative posts regarding clinical trial side effects.

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc